JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Expression of p53 Breast Cancer in Kurdish Women in the West of Iran: a Reverse Correlation with Lymph Node Metastasis
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Expression of p53 Breast Cancer in Kurdish Women in the West of Iran: a Reverse Correlation with Lymph Node Metastasis
Payandeh, Mehrdad; Sadeghi, Masoud; Sadeghi, Edris; Madani, Seyed-Hamid;
  PDF(new window)
 Abstract
Background: In breast cancer (BC), it has been suggested that nuclear overexpression of p53 protein might be an indicator of poor prognosis. The aim of the current study was to evaluate the expression of p53 BC in Kurdish women from the West of Iran and its correlation with other clinicopathology figures. Materials and Methods: In the present retrospective study, 231 patients were investigated for estrogen receptor (ER) and progesterone receptor (PR) positivity, defined as positive tumor cells with nuclear staining. A binary logistic regression model was selected using Akaike Information Criteria (AIC) in stepwise selection for determination of important factors. Results: ER, PR, the human epidermal growth factor receptor 2 (HER2) and p53 were positive in 58.4%, 55.4%, 59.7% and 45% of cases, respectively. Ki67 index was divided into two groups: 54.5% had Ki67<20% and 45.5% had Ki67 . Of 214 patients, 137(64%) had lymph node metastasis and of 186 patients, 122(65.6%) had vascular invasion. Binary logistic regression analysis showed that there was inverse significant correlation between lymph node metastasis (P
 Keywords
Breast cancer;Kurdish ethnicity;P53;receptor expression;lymph node metastasis;
 Language
English
 Cited by
1.
Androgen Receptor Expression and its Correlation with Other Risk Factors in Triple Negative Breast Cancers: a Report from Western Iran,;;;;;

Asian Pacific Journal of Cancer Prevention, 2016. vol.17. 7, pp.3321-3324 crossref(new window)
1.
Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients, Bioengineered, 2017, 8, 4, 383  crossref(new windwow)
 References
1.
Aeinfar M, Najafi S, Payandeh M, Sadeghi M, Sadeghi E (2015). Clinicopathology figures of breast cancer women with brain metastasis and invasive ductal carcinoma. Am J Cancer Prev, 3, 68-71.

2.
Arun B, Kilic G, Yen C, et al (2003). Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes. Cancer, 98, 2554-9. crossref(new window)

3.
Aylon Y, Oren M (2011). New plays in the p53 theater. Curr Opin Genet Dev, 21, 86-92. crossref(new window)

4.
Bertheau P, Steinberg SM, Merino MJ (1998). C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: immunohistochemical analysis and clinicopathologic correlation. Hum Pathol, 29, 323-9. crossref(new window)

5.
Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the Carolina Breast cancer Study. JAMA, 295, 2492-502. crossref(new window)

6.
De Azambuja E, Cardoso F, De Castro G, et al (2007). Ki67 as prognostic marker in early breast cancer: a meta-analysis of pub-lished studies involving 12.155 patients. Br J Cancer, 96, 1504-13. crossref(new window)

7.
el-A Helal T, Khalifa A, Kamel AS (2000). Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt. Anticancer Res, 20, 2145-50.

8.
Howard EM, Lau SK, Lyles RH, et al (2004). Correlation and expression of p53, HER-2, vascular endothelial growth factor (VEGF), and e-cadherin in a high-risk breast-cancer population. Int J Clin Oncol, 9, 154-60.

9.
Jasar Dz, Smichkoska S, Kubelka K, Filipovski V, Petrushevska G (2015). Expression of p53 protein product in triple negative breast cancers and relation with clinical and histopathological parameters. Prilozi, 36, 69-79.

10.
Lacroix M, Toillon RA, Leclercq G (2006). p53 and breast cancer, an update. Endocr Relat Cancer, 13, 293-325. crossref(new window)

11.
Li X, Wang Q, Fu L, Liu M, Yu X (2015). Expression of PTEN, p53 and EGFR in the molecular subtypes of breast carcinoma and the correlation among them. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 40, 973-8 (in Chinese).

12.
Osanai T, Takagi Y, Toriya Y, et al (2005). Inverse correlation between the expression of O6-methylguanine-DNA methyl transferase (MGMT) and p53 in breast cancer. Jpn J Clin Oncol, 35, 121-5. crossref(new window)

13.
Payandeh M, Malayeri R, Sadeghi M, Sadeghi E, Gholami, F (2015c). Expression of p53 and Ki67 in the patients with triple negative breast cancer and invasive ductal carcinoma. Am J Cancer Prev, 3, 58-61.

14.
Payandeh M, Sadeghi M, Sadeghi E, Aeinfar M (2015a). Clinicopathology figures and long-term effects of tamoxifen plus radiation on survival of women with invasive ductal carcinoma and triple negative breast cancer. Asian Pac J Cancer Prev, 16, 4863-7. crossref(new window)

15.
Payandeh M, Sadeghi M, Sadeghi E (2015b). Differences in prognostic factors between early and late recurrence breast cancers. Asian Pac J Cancer Prev, 16, 6575-9. crossref(new window)

16.
Pharoah PD, Day NE, Caldas C (1999). Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer, 80, 1968-73. crossref(new window)

17.
Qing Z, Zou W, Luo J, Wen Q, Fan S (2014). [p53 protein expression in HER2-negative breast invasive ductal carcinoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 39, 1016-22.

18.
Rakha EA, El-Sayed ME, Green AR, et al (2007). Prognostic markers in triple negative breast cancer. Cancer, 109, 25-32. crossref(new window)

19.
Shapochka DO, Zaletok SP, Gnidyuk MI (2012). Relationship between NF-${\kappa}B$, ER, PR, Her2/neu, Ki67, p53 expression in human breast cancer. Exp Oncol, 34, 358-63.

20.
Sirvent JJ, Salvado MT, Santafe M, et al (1995). p53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (ki-67) and c-erbB-2. Immunohistochemical study of 153 cases. Histol Histopathol, 10, 531-9.

21.
Sjostrom-Mattson J, Von Boguslawski K, Bengtsson NO, et al (2009). The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer. Acta Oncol, 48, 1137-43. crossref(new window)

22.
Temmim L, Baker H, Sinowatz F (2001). Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women. Anticancer Res, 21, 743-8.

23.
Vernet-Tomas M, Banos N, Sabadell D, et al (2015). p53 expression in breast cancer predicts tumors with low probability of non-sentinel nodes infiltration. J Obstet Gynaecol Res, 41, 1115-21. crossref(new window)

24.
Voduc KD, Cheang MC, Tyldesley S, et al (2010). Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol, 28, 1684-91. crossref(new window)

25.
Wang XZ, Liu Q, Sun JJ, et al (2015). Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification. Genet Mol Res, 14, 4282-90. crossref(new window)